18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis
- PMID: 27754904
- DOI: 10.2967/jnumed.116.180075
18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis
Abstract
In patients with brain metastasis, PET using labeled amino acids has gained clinical importance, mainly regarding the differentiation of viable tumor tissue from treatment-related effects. However, there is still limited knowledge concerning the uptake characteristics in patients with newly diagnosed and untreated brain metastases. Hence, we evaluated the uptake characteristics in these patients using dynamic O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET. Methods: Patients with newly diagnosed brain metastases without prior local therapy and 18F-FET PET scanning were retrospectively identified in 2 centers. Static and dynamic PET parameters (maximal/mean tumor-to-brain-ratio [TBRmax/TBRmean], biologic tumor volume [BTV], and time-activity curves with minimal time to peak [TTPmin]) were evaluated and correlated with MRI parameters (maximal lesion diameter, volume of contrast enhancement) and originating primary tumor. Results: Forty-five brain metastases in 30 patients were included. Forty of 45 metastases (89%) had a TBRmax ≥ 1.6 and were classified as 18F-FET-positive (median TBRmax, 2.53 [range, 1.64-9.47]; TBRmean, 1.86 [range, 1.63-5.48]; and BTV, 3.59 mL [range, 0.04-23.98 mL], respectively). In 39 of 45 brain metastases eligible for dynamic analysis, a wide range of TTPmin was observed (median, 22.5 min; range, 4.5-47.5 min). All 18F-FET-negative metastases had a diameter of ≤ 1.0 cm, whereas metastases with a > 1.0 cm diameter all showed pathologic 18F-FET uptake, which did not correlate with lesion size. The highest variability of uptake intensity was observed within the group of melanoma metastases. Conclusion: Untreated metastases predominantly show increased 18F-FET uptake, and only a third of metastases < 1.0 cm were 18F-FET-negative, most likely because of scanner resolution and partial-volume effects. In metastases > 1.0 cm, 18F-FET uptake intensity was highly variable and independent of tumor size (even intraindividually). 18F-FET PET might provide additional information beyond the tumor extent by reflecting molecular features of a metastasis and might be a useful tool for future clinical applications, for example, response assessment.
Keywords: 18F-FET PET; brain metastasis; kinetic analysis.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.
Similar articles
-
Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties?Radiat Oncol. 2016 Oct 21;11(1):139. doi: 10.1186/s13014-016-0713-8. Radiat Oncol. 2016. PMID: 27769279 Free PMC article.
-
Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?J Nucl Med. 2016 Aug;57(8):1177-82. doi: 10.2967/jnumed.115.171033. Epub 2016 Mar 31. J Nucl Med. 2016. PMID: 27033893
-
Role of O-(2-(18)F-fluoroethyl)-L-tyrosine PET for differentiation of local recurrent brain metastasis from radiation necrosis.J Nucl Med. 2012 Sep;53(9):1367-74. doi: 10.2967/jnumed.112.103325. Epub 2012 Aug 7. J Nucl Med. 2012. PMID: 22872742
-
Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine (FET).Methods. 2017 Nov 1;130:124-134. doi: 10.1016/j.ymeth.2017.05.019. Epub 2017 May 24. Methods. 2017. PMID: 28552264 Review.
-
O-(2-[18F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results.Curr Radiopharm. 2019;12(3):201-210. doi: 10.2174/1874471012666190111111046. Curr Radiopharm. 2019. PMID: 30636621 Review.
Cited by
-
Qualitative and quantitative analysis of 18F-GP1 positron emission tomography in thrombotic cardiovascular disease.Sci Rep. 2024 Nov 5;14(1):26792. doi: 10.1038/s41598-024-77151-w. Sci Rep. 2024. PMID: 39500930 Free PMC article.
-
Negative 18F-FET PET/CT in brain metastasis recurrence: a teaching case report.Eur J Hybrid Imaging. 2021 Nov 22;5(1):21. doi: 10.1186/s41824-021-00115-0. Eur J Hybrid Imaging. 2021. PMID: 34806124 Free PMC article.
-
[18F]FET PET Uptake Indicates High Tumor and Low Necrosis Content in Brain Metastasis.Cancers (Basel). 2021 Jan 19;13(2):355. doi: 10.3390/cancers13020355. Cancers (Basel). 2021. PMID: 33478030 Free PMC article.
-
Current status of PET imaging in neuro-oncology.Neurooncol Adv. 2019 May 28;1(1):vdz010. doi: 10.1093/noajnl/vdz010. eCollection 2019 May-Dec. Neurooncol Adv. 2019. PMID: 32642650 Free PMC article. Review.
-
Evaluation of the Performance of 18F-Fluorothymidine Positron Emission Tomography/Computed Tomography (18F-FLT-PET/CT) in Metastatic Brain Lesions.Diagnostics (Basel). 2019 Jan 26;9(1):17. doi: 10.3390/diagnostics9010017. Diagnostics (Basel). 2019. PMID: 30691084 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical